CO41 Real-World Outcomes of Nusinersen or Onasemnogene Abeparvovec (OA) Monotherapy, or Switching to OA from Nusinersen in SMA Patients Aged ≥6 Months
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.115
https://www.valueinhealthjournal.com/article/S1098-3015(23)00215-2/fulltext
Title :
CO41 Real-World Outcomes of Nusinersen or Onasemnogene Abeparvovec (OA) Monotherapy, or Switching to OA from Nusinersen in SMA Patients Aged ≥6 Months
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00215-2&doi=10.1016/j.jval.2023.03.115
First page :
Section Title :
Open access? :
No
Section Order :
10577